Literature DB >> 9271260

Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.

J A Harding1, C M Engbers, M S Newman, N I Goldstein, S Zalipsky.   

Abstract

Immunoliposomes composed of hydrogenated soy phosphatidylcholine, cholesterol, methoxypoly(ethylene glycol)-distearoyl phosphatidylethanolamine (mPEG-DSPE), and hydrazide-PEG-DSPE (mole ratio, 57:38:3.3:1.7) linked to periodate-oxidized chimerized mouse IgG (C225, anti-human epidermal growth factor receptor) were prepared by an optimized aggregation-free procedure. The antigen-binding activity of the immunoliposomes was well preserved. When injected intravenously into naive rats, the immunoliposomes (approximately 18 IgG per 100 nm liposome) exhibited long circulation times (MRT = 8.5 h, Cl = 0.2 ml/h). Subsequent injections of the immunoliposomes into the same animals resulted in rapid clearance (MRT < or = 0.7 h, Cl > or = 7 ml/h), which was accompanied by a significant increase in anti-C225 specific titers. Upon repeated injection or coinjection with the parent liposomes free C225 consistently exhibited prolonged circulation without any increase in C225-specific antisera, but was cleared quickly when administered into animals that had been pretreated with the immunoliposomes. Screening of the immunoliposome induced antisera against human polyclonal IgG and C225-derived Fab' fragment revealed that the immune response was specifically triggered by the constant human region of C225. These results demonstrate that the preparations of PEG-grafted immunoliposomes are more immunogenic than the free IgG component, which is of profound importance to the antibody-mediated liposomal drug delivery effort.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271260     DOI: 10.1016/s0005-2736(97)00056-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

1.  Molecular ultrasound imaging and its potential for paediatric radiology.

Authors:  Isabel Kiessling; Jessica Bzyl; Fabian Kiessling
Journal:  Pediatr Radiol       Date:  2010-08-03

Review 2.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

3.  Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting.

Authors:  Melissa L Geddie; Neeraj Kohli; Dmitri B Kirpotin; Maja Razlog; Yang Jiao; Tad Kornaga; Rachel Rennard; Lihui Xu; Birgit Schoerberl; James D Marks; Daryl C Drummond; Alexey A Lugovskoy
Journal:  MAbs       Date:  2016-11-17       Impact factor: 5.857

4.  Is Tumor Cell Specificity Distinct from Tumor Selectivity In Vivo?: A Quantitative NIR Molecular Imaging Analysis of Nanoliposome Targeting.

Authors:  Girgis Obaid; Kimberley Samkoe; Kenneth Tichauer; Shazia Bano; Yeonjae Park; Zachary Silber; Sassan Hodge; Susan Callaghan; Mina Guirguis; Srivalleesha Mallidi; Brian Pogue; Tayyaba Hasan
Journal:  Nano Res       Date:  2020-11-27       Impact factor: 8.897

5.  Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases.

Authors:  G A Koning; H W Morselt; A Gorter; T M Allen; S Zalipsky; J A Kamps; G L Scherphof
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

6.  Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab'-Immunoliposomes for Gene Silencing in Breast Cancer Cells.

Authors:  Arif Khan; Masood A Khan; Ahmed N Aljarbou; Yousef H Aldebasi; Khaled S Allemailem; Mohammed A Alsahli; Shamshir Khan; Abdulmohsen M Alruwetei
Journal:  Int J Nanomedicine       Date:  2020-08-05

7.  Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison.

Authors:  Gerben A Koning; Henriëtte W M Morselt; Arko Gorter; Theresa M Allen; Samuel Zalipsky; Gerrit L Scherphof; Jan A A M Kamps
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

Review 8.  Sheddable coatings for long-circulating nanoparticles.

Authors:  Birgit Romberg; Wim E Hennink; Gert Storm
Journal:  Pharm Res       Date:  2007-06-06       Impact factor: 4.200

Review 9.  Multifunctional and stimuli-sensitive pharmaceutical nanocarriers.

Authors:  Vladimir Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2008-10-17       Impact factor: 5.571

10.  What NIR photodynamic activation offers molecular targeted nanomedicines: Perspectives into the conundrum of tumor specificity and selectivity.

Authors:  Chanda Bhandari; Mina Guirguis; N Anna Savan; Navadeep Shrivastava; Sabrina Oliveira; Tayyaba Hasan; Girgis Obaid
Journal:  Nano Today       Date:  2020-12-16       Impact factor: 20.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.